AEON Biopharma (AEON) Convertible Debt (2020 - 2026)
AEON Biopharma (AEON) posted Convertible Debt of $34.6 million for Q4 2025, up 102.92% sequentially from $17.1 million in Q3 2025, and up 196.0% YoY from $11.7 million in Q4 2024.
AEON Biopharma (AEON) Convertible Debt (2020 - 2026) Analysis & Trends
AEON Biopharma has reported Convertible Debt for 6 years, with the latest figure at $34.6 million in Q4 2025.
- Quarterly Convertible Debt rose 196.0% year-over-year to $34.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.6 million (up 196.0% YoY) and the FY2025 annual result came in at $34.6 million, up 196.0% from the prior year.
- Convertible Debt rose to $34.6 million in Q4 2025 per AEON's latest filing, from $17.1 million in the prior quarter.
- Over five years, Convertible Debt peaked at $60.4 million in Q4 2022 and troughed at $5.1 million in Q1 2024.
- A 5-year average of $20.1 million and a median of $15.2 million in 2025 frame the typical range for Convertible Debt.
- The sharpest annual moves came in 2021 and 2022: Convertible Debt tumbled 42.81% in 2021, then jumped 245.29% in 2022.
- Over 5 years, Convertible Debt stood at $17.5 million in 2021, then surged by 245.29% to $60.4 million in 2022, then plunged by 71.04% to $17.5 million in 2023, then tumbled by 33.21% to $11.7 million in 2024, then jumped by 196.0% to $34.6 million in 2025.
- According to Business Quant data, Convertible Debt over the past three periods registered $34.6 million, $17.1 million, and $15.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - |
| 10 | AEON Biopharma | 9.60 Mn | 6.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Dec 31, 2025 | 34.60 Mn |
| Sep 30, 2025 | 17.05 Mn |
| Jun 30, 2025 | 15.17 Mn |
| Mar 31, 2025 | 13.32 Mn |
| Dec 31, 2024 | 11.69 Mn |
| Sep 30, 2024 | 15.17 Mn |
| Jun 30, 2024 | 13.29 Mn |
| Mar 31, 2024 | 5.09 Mn |
| Sep 30, 2023 | 17.50 Mn |
| Dec 31, 2022 | 60.43 Mn |
| Dec 31, 2021 | 17.50 Mn |
| Dec 31, 2020 | 30.60 Mn |